AstraZeneca chief calls on industry to rebuild trust
This article was originally published in Scrip
David Brennan, CEO at AstraZeneca, told a gathering of pharma sector leaders that the industry needs to rebuild public trust of all stakeholders if it is to remain successful. Speaking at the 25th International Federation of Pharmaceutical and Manufacturers & Associations (IFPMA) assembly, Mr Brennan used part of his inaugural speech as the new IFPMA president, to remind his peers that industry cannot work in a vacuum to tackle the world's healthcare challenges and needs to reach out and collaborate with other stakeholders.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.